Comparative Effects of Umbilical Cord- and Menstrual Blood-Derived MSCs in Repairing Acute Lung Injury

Abstract

Mesenchymal stem cells (MSCs) can effectively relieve acute lung injury (ALI) in several in vivo models. However, the underlying mechanisms and optimal sources of MSCs are unclear. In the present study, we investigated the effects of umbilical cord- (UC-) and menstrual blood- (MB-) derived MSCs on ALI. MSCs were transplanted into a lipopolysaccharide-induced ALI mouse model, and the therapeutic effects were determined by histological, cellular, and biochemical analyses. Our results showed that both UCMSC and MBMSC transplantation inhibited the inflammatory response and promoted lung tissue repair. UCMSC treatment resulted in reduced damage and inflammation in the lung tissue and enhanced protection of lung function. Furthermore, we found that UCMSCs secreted higher levels of anti-inflammatory cytokines (interleukin-10 and keratinocyte growth factor) in ALI-related conditions, which may be due to the greater therapeutic capacity of UCMSCs compared with MBMSCs. These findings suggest that MSCs protected the lipopolysaccharide-induced ALI model by regulating inflammation, most likely via paracrine factors. Moreover, MSCs derived from the UC may be a promising alternative for ALI treatment.

Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application

“…Similarly, MenSC injection improved acute lung injury scores through normalization of lung O 2 pressure. MenSC reduced neutrophil frequency, myeloperoxidase activity, and pro-inflammatory cytokines levels in bronchoalveolar fluid (Ren et al, 2018). MenSC injection also reduced inflammation and collagen deposition in a mouse model of bleomycin-induced pulmonary fibrosis (Zhao et al, 2018b).…”

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

“…Moreover, ARDS affects the immunomodulatory effects of bone marrow MSCs and impairs their potential use for autologous transplantation (Antebi et al, 2018). Although several studies have evaluated the therapeutic effects of MSCs from other sources in ARDS (Zheng et al, 2014;Ren et al, 2018;Silva et al, 2018), it remains unclear about which one may provide superior therapeutic effects. Cell doses are critical for the clinical use of MSC therapy.…”

Mesenchymal Stromal Cells Attenuate Infection-Induced Acute Respiratory Distress Syndrome in Animal Experiments: A Meta-Analysis

“…9 had no extractable data. 20 Male ICR mice E. coli at 10 7 CFUs, IT Human UC MSCs 1 Â 10 5 cells, IT 1, 3, and 7 days postinjury Jerkic et al 21 Adult male SD rats E. coli (2 to 3 Â 10 9 CFUs), IT 23 Adult SD rats LPS (6 mg/kg), IP Human AD MSCs 5 Â 10 5 cells, IV 24, 48, and 72 h after MSC injection Curley et al 24 Male SD rats E. coli (1.5 to 2 Â 10 9 CFU/kg), IT Human UC MSCs 1 Â 10 7 cells, IV 24 or 48 h after modeling Han et al 25 Male C57BL/ 6 mice LPS, IT Mice BM MSCs 5 Â 10 5 cells, IV 24 or 72 after MSC injection Hao et al 26 Male 36 Female SD rats LPS (10 mg/kg), IP Human UC MSCs 5 Â 10 5 cells, IV 1, 7, and 14 days postinjection of LPS Li JW et al 37 Male SD rats LPS (10 mg/kg), IV Rat BM MSCs 5 Â 10 5 cells, IV 2, 24, and 72 h after MSC treatment Li J et al 38 Male SD rats LPS (10 mg/kg), IP Human UC MSCs 5 Â 10 5 cells, IV 48 h after MSC treatment Lang et al 39 Male 49 Male SD rats LPS (7 mg/kg), IT Rat BM MSCs 2 Â 10 6 cells, intrapleural 1, 3, and 7 days after modeling Ren et al 50 Male 53 Adult BALB/ c mice LPS (10 mg/g), intranasal…”